comparemela.com

Latest Breaking News On - Oncology investor - Page 7 : comparemela.com

Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products.

United statesShawnm lelandExchange commissionPrnewswire elevation oncology incAmerican society of clinical oncologyElevation oncology incMegalith biopharmaceutical co ltdCorporate communications investor relationsChief executive officerClinical oncologyAnnual meetingElevation oncologyUpcoming milestonesGroup limitedLooking statementsPrivate securities litigation reform act

Celyad Oncology SA (CYAD) Provides Strategic Update

Celyad Oncology SA (CYAD) Provides Strategic Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mont saint guibertWaals gewestNew yorkUnited statesSara zelkovicMichel lussierExchange commissionCommunications investor relationsWall streetMetastatic colorectal cancerClinical holdPrivate securities litigation reform actCelyad oncologyAnnual reportOncology investorMedia contact

Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across.

Shawnm lelandExchange commissionPrnewswire elevation oncology incElevation oncology incMegalith biopharmaceutical co ltdDrug administrationCorporate communications investor relationsFast trackChief executive officerElevation oncologyAccelerated approvalPriority reviewGroup limitedUpcoming milestonesLooking statementsPrivate securities litigation reform act

Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for.

Shawnm lelandPrnewswire elevation oncology incCompany investor relationsElevation oncology incCorporate communications investor relationsChief executive officerElevation oncologyWedbush pacgrow healthcare conferenceInvestor relationsOncology investorCorporate communications

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18 2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products.

United statesHong kongShawnm lelandDavid dornanZhang cuilongMegalith biopharmaceutical co ltdDrug administrationCorporate communications investor relationsExchange commissionPrnewswire elevation oncology incGroup limitedHong kong stock exchangeElevation oncology incGreater chinaElevation oncologyChief executive officer

vimarsana © 2020. All Rights Reserved.